Compare DexCom, Inc. (DXCM) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

IDRV trades at $36.50, down 0.44% with bearish technical signals showing 17 sell indicators versus 1 buy. The electric vehicle ETF faces mixed sentiment as global EV sales show growth momentum while US adoption lags behind Europe and China. Technical analysis indicates strong bearish pressure with all moving averages signaling sell, though oscillators suggest potential oversold conditions with RSI readings near 31-32.

The EV sector faces regulatory uncertainty and competitive pressures despite positive global sales trends. Investment appeal depends on broader EV adoption rates and policy developments, with risks including US-China trade tensions and shifting consumer preferences. The sector's growth trajectory remains intact but faces near-term headwinds from economic conditions and market saturation concerns.